262 related articles for article (PubMed ID: 11870561)
1. [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks].
Gabius S; Gabius HJ
Dtsch Med Wochenschr; 2002 Mar; 127(9):457-9. PubMed ID: 11870561
[No Abstract] [Full Text] [Related]
2. Evaluating unconventional therapies.
Hajto T; Saller R
CMAJ; 1998 Oct; 159(7):759; author reply 759, 761. PubMed ID: 9805018
[No Abstract] [Full Text] [Related]
3. [Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties].
Mengs U; Witthohn K; Schwarz T; Lentzen H
Wien Med Wochenschr; 1999; 149(8-10):262-4. PubMed ID: 10483695
[TBL] [Abstract][Full Text] [Related]
4. Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review.
Bocci V
J Biol Regul Homeost Agents; 1993; 7(1):1-6. PubMed ID: 8346712
[TBL] [Abstract][Full Text] [Related]
5. [Ingredients of mistletoe (Viscum album L.) as potential drugs].
Franz H
Pharmazie; 1985 Feb; 40(2):97-104. PubMed ID: 3889937
[No Abstract] [Full Text] [Related]
6. Mistletoe or not mistletoe is still the question.
Kiene H; Büschel G; Hornebar M
Forsch Komplementarmed Klass Naturheilkd; 2001 Oct; 8(5):309-12. PubMed ID: 11760713
[No Abstract] [Full Text] [Related]
7. [Comment on S. Gabius, H.-J. Gabius: Immune modulating mistletoe therapy by lectin standardization: a double-edged sword?].
Wetzel D; Mengs U; Schwarz T
Versicherungsmedizin; 2000 Mar; 52(1):38-40. PubMed ID: 10718092
[No Abstract] [Full Text] [Related]
8. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.
Huber R; Lüdtke R; Klassen M; Müller-Buscher G; Wolff-Vorbeck G; Scheer R
Eur J Med Res; 2001 Sep; 6(9):399-405. PubMed ID: 11669085
[TBL] [Abstract][Full Text] [Related]
9. [Lectin compared to mistletoe use: experimental therapy form with preclinically verified risk potential].
Kuehn JJ; Kovacs E
Dtsch Med Wochenschr; 2002 Dec; 127(49):2637; author reply 2638. PubMed ID: 12469281
[No Abstract] [Full Text] [Related]
10. Immunoprotective activity of the galactoside-specific mistletoe lectin in cortisone-treated BALB/c-mice.
Beuth J; Ko HL; Tunggal L; Buss G; Jeljaszewicz J; Steuer MK; Pulverer G
In Vivo; 1994; 8(6):989-92. PubMed ID: 7772751
[TBL] [Abstract][Full Text] [Related]
11. Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1.
Beuth J; Ko HL; Tunggal L; Steuer MK; Geisel J; Jeljaszewicz J; Pulverer G
In Vivo; 1993; 7(5):407-10. PubMed ID: 8110981
[TBL] [Abstract][Full Text] [Related]
12. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks.
Dohmen W; Breier M; Mengs U
Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652
[TBL] [Abstract][Full Text] [Related]
13. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research.
Stauder H; Kreuser ED
Onkologie; 2002 Aug; 25(4):374-80. PubMed ID: 12232491
[TBL] [Abstract][Full Text] [Related]
14. [The mistletoe myth--claims, reality and provable perspectives].
Gabius HJ; André S; Kaltner H; Siebert HC; von der Lieth CW; Gabius S
Z Arztl Fortbild (Jena); 1996 Apr; 90(2):103-10. PubMed ID: 8686332
[TBL] [Abstract][Full Text] [Related]
15. Further refinement of the description of the ligand-binding characteristics for the galactoside-binding mistletoe lectin, a plant agglutinin with immunomodulatory potency.
Galanina OE; Kaltner H; Khraltsova LS; Bovin NV; Gabius HJ
J Mol Recognit; 1997; 10(3):139-47. PubMed ID: 9408830
[TBL] [Abstract][Full Text] [Related]
16. Internalization and action of an immunotoxin containing mistletoe lectin A-chain.
Wiedłocha A; Sandvig K; Walzel H; Radzikowsky C; Olsnes S
Cancer Res; 1991 Feb; 51(3):916-20. PubMed ID: 1988131
[TBL] [Abstract][Full Text] [Related]
17. From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe?
Gabius HJ; Gabius S; Joshi SS; Koch B; Schroeder M; Manzke WM; Westerhausen M
Planta Med; 1994 Feb; 60(1):2-7. PubMed ID: 8134410
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of immunoactive mistletoe lectin-I.
Beuth J
Anticancer Drugs; 1997 Apr; 8 Suppl 1():S53-5. PubMed ID: 9179369
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of Viscum album lectin ML-1 and fresh plant extract (Isorel) on the cell growth in vitro and tumorigenicity of melanoma B16F10.
Zarković N; Kalisnik T; Loncarić I; Borović S; Mang S; Kissel D; Konitzer M; Jurin M; Grainza S
Cancer Biother Radiopharm; 1998 Apr; 13(2):121-31. PubMed ID: 10850348
[TBL] [Abstract][Full Text] [Related]
20. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract.
Klein R; Classen K; Fischer S; Errenst M; Scheffler A; Stein GM; Scheer R; von Laue HB
Eur J Med Res; 2002 Aug; 7(8):359-67. PubMed ID: 12204844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]